ArticleACS omega2026
Increased Flexibility and Hemocompatibility of NO-Releasing Small Diameter Vascular Grafts in an Ex Vivo Sheep Model.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Addressing global cardiovascular morbidity, the high thrombogenicity, occlusion, and failure risk in small-diameter vascular grafts (SDVGs, <6 mm) necessitate regenerative SDVGs with antithrombotic properties. In this study, a previously developed nanoengineered controlled release system of nitric oxide (NO) was now preclinically investigated in a 3D printed polylactic acid SDVG using an ex vivo arteriovenous shunt model in sheep. Thrombogenicity of the NO releasing SDVGs was evaluated by short-term (30 min) and long-term (2 h) clot formation. To facilitate future long-term implantation, the flexibility of the cast SDVGs was customized by tailoring Young's modulus of polycaprolactone to closely mimic the native vascular tissue. Ex vivo assessments demonstrated that NO releasing grafts significantly reduced thrombus formation with significantly lower clot weights (0 to 4 mg) compared with control grafts (16.42 ± 4.65 mg,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.